Home › Medulloblastoma › NCT07085325

CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

Who can join

All ages · All sexes

Inclusion Criteria:

* Diagnosis of any subtype of medulloblastoma between the ages of 3 to 22 years or between the ages of 22 to 44 years with the sonic hedgehog (SHH) subtype of medulloblastoma
* Radiotherapy on or according to the SJMB12 protocol
* Received radiotherapy at St. Jude Children's Research Hospital
* 5 or more years since the initiation of radiation therapy and who did not have evidence of disease progression
* Provision of informed consent by participant/guardian or legal representative; Assent by minor participant
* Participants may choose to complete all or a subset of the proposed assessments; refusal to participate in some aspects of the study will not preclude participant inclusion
* Participants must also complete enrollment on SJLIFE

Exclusion Criteria:

* Participants or their legal guardian/representative are unwilling or unable to provide written informed consent.
* Participants who had relapsed or refractory disease during or following completion of treatment for medulloblastoma

About the study

The study is being done to learn more about the long-term health and well-being of participants treated for medulloblastoma. The study is to decide which evaluations focusing on therapy-related lasting effects (or toxicities) should be considered.

Medulloblastoma outcomes have improved with contemporary therapies including modern neurosurgical techniques and risk-adapted radiotherapy and chemotherapy regimens. However, survivors remain at risk for long-term health problems such as neurocognitive deficits, hearing loss, impaired cardiorespiratory fitness and physical performance, cardiac and neuroendocrine dysfunction, musculoskeletal conditions, and infertility.

Sponsor: St. Jude Children's Research Hospital · Participants: 184 · Started: Apr 20, 2026

Contact the study team

• Thomas E Merchant, DO, PhD · Phone: 888-226-4343

Official record on ClinicalTrials.gov — NCT07085325

Locations in the U.S.

Conditions

• Medulloblastoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.